CCPN SPAF Tool vs Probiotic Guide Canada

Stroke prevention for your patients with atrial fibrillation The Canadian Cardiovascular Pharmacist Network (CCPN) SPAF Tool App is designed to assist Canadian healthcare professionals optimize stroke prevention treatment in their patients with nonvalvular atrial fibrillation. It was modeled after the CCPN SPAF pocket card. It incorporates stroke risk stratification using CHADS and CHADSVASc criteria, bleeding risk using HAS-BLED criteria and provides recommendations for stroke prevention therapy based on the Canadian Cardiovascular Society (CCS) AFIB Guidelines. This app also includes practical drug information, dose recommendations, creatinine clearance calculations, and management tools which allow healthcare professionals to compare therapeutic options and tailor therapy for individual patients. It is intended as a general reference to supplement the existing knowledge of healthcare professionals. This app was supported in kind by the Centre for Innovation in Complex Care (CICC) and through an unrestricted grant from the Pfizer-Bristol Myers Squibb Alliance and Servier Canada. The original CCPN SPAF pocket card was supported through an unrestricted grant from Boehringer Ingelheim Canada 

For use by Canadian healthcare professionals only.

WHAT is this: A Practice Tool to Assist with Clinical Decision Making for Appropriate Probiotic Therapy for Your Patients WHO is the intended user: This Clinical Guide is designed to translate scientific evidence available for probiotic products to practical, clinically relevant information. It is intended to be used as clinical decision-making tool, enabling clinicians to easily select the appropriate product, dose, and formulation for a specific indication. WHY is this needed: Currently, the body of evidence for probiotic interventions is growing along with popular demand for these products. There is evidence to support the use of probiotic products for a variety of indications beyond gut health, however applications and results are strain-specific. Due to frequent changes in commercial availability of probiotic strains, new published evidence and growing research, an annual review and updates of this Clinical Guide have been conducted since 2008. A general lack of adverse effects attributable to probiotics supports the wide use of these products, but ongoing investigation is recommended.